Objective Twenty years after the discovery of human immunodeficiency virus (HIV)as the causative agent of the acquired immune deficiency syndrome (AIDS) a vaccine to prevent virus infection or mitigate disease is still not available. Accumulating data suggest that CD8-positive T cells play an important role in the control of HIV in the infected host. Therefore, several vaccine strategies based on DNA or recombinant viral or bacterial vectors have been devised to induce this type of immune response, and some of th ese vaccines are in early clinical testing. This proposal aims at demonstrating the safety and immunogenicity in humans of a novel recombinant measles virus (MV) vector for use as an AIDS vaccine. The vector is replication competent in vivo and is deriv ed from a widely used measles vaccine strain (Schwarz), which is known to induce very long lasting immunity. Therefore, this novel vector potentially offers a unique combination of safety and potency. The recombinant HIV MV vectors will express three re latively conserved HIV proteins (Gag, Pol, Nef) from HIV clade B and A strains. A good manufacturing practices (GMP) compatible production process for the recombinant MV vector will be developed and a GMP lot will be produced for two clinical studies. Th e first study will evaluate the safety profile of the MV vector, while the second study will assess in addition the immunogenicity in MV-immune volunteers. With these two clinical studies, the project will specifically address potential shedding of the r ecombinant vector into the environment and the potential negative impact of pre-existing MV immunity. It is expected that at the end of the project sufficient clinical data on the safety and immunogenicity will have been generated to decide on subsequent advanced technical and clinical development of this novel vaccine approach. Fields of science natural sciencesbiological sciencesmicrobiologyvirologynatural sciencesbiological sciencesgeneticsDNAmedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2004-2.3.0-1 - Development of new HIV/AIDS vaccine approaches Call for proposal FP6-2004-LIFESCIHEALTH-5 See other projects for this call Funding Scheme IP - Integrated Project Coordinator GLAXOSMITHKLINE BIOLOGICALS SA EU contribution No data Address Rue de l'Institut 89 --- RIXENSART Belgium See on map Total cost No data Participants (5) Sort alphabetically Sort by EU Contribution Expand all Collapse all INSTITUT PASTEUR France EU contribution No data Address Rue du Docteur Roux 25-28 PARIS See on map Links Website Opens in new window Total cost No data UNIVERSITEIT GENT Belgium EU contribution No data Address Sint Pietersnieuwstraat 25 GENT See on map Links Website Opens in new window Total cost No data ST. GEORGE'S - UNIVERSITY OF LONDON (PREV.: ST. GEORGE'S HOSPITAL MEDICAL SCHOOL) United Kingdom EU contribution No data Address Cranmer Terrace LONDON See on map Links Website Opens in new window Total cost No data THE HEALTH PROTECTION AGENCY United Kingdom EU contribution No data Address Central Office - 7th Floor, Holborn Gate - High Holborn 330 LONDON See on map Links Website Opens in new window Total cost No data ASSITANCE PUBLIQUE - HÔPITAUX DE PARIS - CIC COCHIN France EU contribution No data Address 3, avenue Victoria PARIS See on map Links Website Opens in new window Total cost No data
